The Hustle
August 11, 2026
TL;DR
Colossal Biosciences is using ancient mammoth DNA to develop gene-editing technology valued at $10.2 billion, with the true goal being to master biological programming for future human applications.
“Strategically, it's less about the mammoths and more about the capability. It's learning how to program biology in order to control certain outcomes, and someday that could apply to us.”
— Investor
“If you give them that range, that capability, that would be a completely different world.”
— Speaker
1. The Mammoth and the Investment
Yuka, a 40,000-year-old woolly mammoth specimen, is driving billions in investor funding into Colossal Biosciences, a company focused on de-extinction technology.
2. The Real Mission Beyond De-extinction
Colossal's $10.2 billion valuation is built not on mammoths themselves but on developing the capability to 'program biology' and control genetic outcomes.
3. Transformative Applications for Humanity
The gene-editing technology could enable humans to customize lifespan (living to 150 or 80) and genetic traits, creating unprecedented control over human biology.